Trial Profile
A Canadian Prospective Nonrandomized Study of Autologous Cell Therapy for Female Stress Urinary Incontinence
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2021
Price :
$35
*
At a glance
- Drugs Iltamiocel (Primary)
- Indications Stress incontinence; Urinary incontinence
- Focus Adverse reactions
- Sponsors Cook MyoSite
- 08 Jun 2017 New trial record
- 16 May 2017 Results from NCT00847535, NCT01008943 and NCT01382602 studies, presented at the 112th Annual Meeting of the American Urological Association.